State Legislative News

Speaker DeLeo Named MassBio 2014 Legislator of the Year at Policy Breakfast

Bob Deleo

Read the blog post recap on the Policy Breakfast here.

Watch videos from the event here.

MassBio Hosts Gubernatorial Candidate Forum

On October 6th, 2014, MassBio hosted a Gubernatorial Candidate Forum sponsored by Amgen and Biogen Idec.  Approximately 200 member company representatives attended the event at the Royal Sonesta in Cambridge.

Republican nominee, Charlie Baker, and the Democratic nominee, Attorney General Martha Coakley, appeared on stage separately in a fireside chat format.

The discussion was moderated by MassBio President and CEO, Robert Coughlin.  The candidates answered questions from panelists, Victoria Blatter, Senior Vice President, US Government Affairs, Amgen, Inc., and John Cox, Executive Vice President, Pharmaceutical Operations and Technology, Biogen Idec.

Among the topics discussed by the candidates were: the Life Science Initiative (LSI), seed funding for start-ups, programs to support manufacturing in life sciences, patient access to breakthrough therapies, STEM education and corporate tax policy.

View photos from the event here.

Watch videos from the event here.

Governor Patrick Signs Bill Granting Patient Access to Interchangeable Biologic Medicines

Biosimilars Bill Signing

In June 2014, Massachusetts Governor Deval Patrick signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines in Massachusetts that will ensure both patient access and patient safety. The policies outlined in Chapter 143 align with all five of BIO’s principles on biologic substitution.

View Chapter 143 here.

Read the press release here.

Read MassBio's blog post here.

MassBio and BIO offer testimony in support of interchangeable biosimilars

Robert Coughlin, President and CEO of MassBio, testified at the State House before the Joint Committee on Health Care Financing in favor of legislation that would allow for the substitution of interchangeable biosimilars.  MassBio worked with BIO and member companies to develop a set of five principles that should govern the substitution of biologics.  The legislation being considered by the Committee aligns with these principles and ensures both patient access and patient safety.

View testimony from MassBio here.

View testimony from BIO here.

MassBio Expresses Concerns about Energy Ordinance

MassBio recently expressed concerns about the proposed Building Energy Reporting and Disclosure Ordinance for the City of Boston.  MassBio’s letter to Mayor Menino can be found here.

Geoff MacKay named to Health Policy Commission Advisory Council

MassBio’s Chairman of the Board of Directors, Geoff MacKay, was recently named to the Health Policy Commission (HPC) Advisory Council. In his new role, Geoff Mackay will be joined by representatives from across the health care field to help guide the Health Policy Commission’s implementation of the state’s health care cost containment law. The Council will advise the HPC’s overall operations and policies, provide feedback on a grant program to support new system delivery and payment reform methods, and encourage public and stakeholder engagement in the HPC’s work.  More information on the HPC and the Advisory Council can be found here.

MassBio Supports SFEIR

MassBio expresses support for Supplemental Final Environmental Impact Report (SFEIR) recently submitted by Boston University for the National Emerging Infectious Diseases Laboratories (NEIDL)

View MassBio’s letter on SFEIR.

Policy Leadership Breakfast – January 23, 2013
Biosimilars: Implementing Sound Policies to Ensure Patient Safety

The introduction of biosimilar and interchangeable biologics into clinical practice will present some new challenges that have not historically been present with small molecule generic medicines. Current state rules on substitution will very likely need to be updated or completely re-written in the context of biosimilar and interchangeable biologic medicines.  MassBio’s Policy Leadership Breakfast held in January focused on this very issue.

Listen as our panel discusses the importance of implementing sound policies at the state level to ensure patient safety:

  1. Fritz Bittenbender outlines BIO’s five principles on biologic product substitution
  2. Dr. David Charles discusses the importance of trust in the doctor/patient relationship. 
  3. Professor William Hancock focuses on the need to ensure that global manufacturing is done in a very safe and effective way. 
  4. Susan Nesci advocates for patient access to all medications in a class.


About MassBio

MassBio is a not-for-profit organization committed to advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.

Founded in 1985, MassBio represents over 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.

image of rss iconLatest Updates